ArticleJournal of clinical laboratory analysis2020
Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Review
- Polo-like kinase 4 (PLK4) as a therapeutic target in breast cancer.Carcinogenesis · 2025Review
- Design, synthesis, and biological evaluation of 5-chlorine-2-amino-pyrimidine derivatives as potent PLK4 inhibitors.RSC medicinal chemistry · 2025Article
- High expression of polo-like kinase 4 predicts worse progression-free survival in diffuse large B cell lymphoma patients treated with R-CHOP.World journal of surgical oncology · 2025Article
- PLK4 Inhibition as a Strategy to Enhance Non-Small Cell Lung Cancer Radiosensitivity.Molecular cancer therapeutics · 2025Article
- Role of PLK4 inhibition in cancer therapy.Cancer metastasis reviews · 2025Review
- A Comprehensive Review of Protein Biomarkers for Invasive Lung Cancer.Current oncology (Toronto, Ont.) · 2024Review
- A novel tumor microenvironment-related gene signature with immune features for prognosis of lung squamous cell carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Guidelines on lung adenocarcinoma prognosis based on immuno-glycolysis-related genes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Aberrant expression of polo-like kinase 4 in renal cell carcinoma: Association with clinicopathological characteristics and long-term survival.Oncology letters · 2022Article
- The intercorrelation among CCT6A, CDC20, CCNB1, and PLK1 expressions and their clinical value in papillary thyroid carcinoma prognostication.Journal of clinical laboratory analysis · 2022Article
- Polo-like kinase 4 is associated with advanced TNM stages and reduced survival and its inhibition improves chemosensitivity in colorectal cancer.Oncology letters · 2022Article
- Polo-like kinase (PLK) 5, a new member of the PLK family, serves as a biomarker to indicate anabatic tumor burden and poor prognosis for resectable non-small cell lung cancer.Frontiers in surgery · 2022Article
- NcRNA-Mediated High Expression ofFrontiers in oncology · 2022Article
- Review
- ALKBH4 promotes tumourigenesis with a poor prognosis in non-small-cell lung cancer.Scientific reports · 2021Article
- Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer Management.Molecular cancer therapeutics · 2021Review
- Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy.Frontiers in oncology · 2021Review
- Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.Journal of cancer research and clinical oncology · 2020Article
- Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
- Retracted
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur study aimed to investigate the association of polo-like kinase 4 (PLK4) expression with tumor features as well as survival in non-small cell lung cancer (NSCLC) patients.
methodsFive hundred and sixty NSCLC patients who underwent pulmonary resection were recruited, and their tumor specimens were obtained. Immunohistochemistry (IHC) staining was performed to assess PLK4 expression in tumor specimen. Follow-up documents were reviewed, and the disease-free survival (DFS) and overall survival (OS) were evaluated.
resultsAccording to IHC staining, there were 277 (49.5%) patients with PLK4 low expression and 283 (50.5%) patients with PLK4 high expression. PLK4 high expression was further classified into three different classes: high+, high++, high+++, and 122 (21.8%), 127 (22.7%), 34 (6.1%) patients were with PLK4 high+, high++, high+++ expression, respectively. Polo-like kinase 4 expression was correlated with larger tumor size, LYN metastasis, and higher TNM stage. As for survival, DFS and OS were lower in patients with PLK4 high expression compared with patients with PLK4 low expression. In addition, DFS and OS were the lowest in patients with PLK4 high+++ expression, followed by those with PLK4 high++ expression, PLK4 high+ expression, and then patients with PLK4 low expression. Univariate and multivariate Cox's proportional hazard regression model analyses further disclosed that PLK4 was an independent predictive factor for poor DFS and OS in NSCLC patients.
conclusionOur study preliminarily illuminates the clinical implication of PLK4 in NSCLC, while further studies are still needed to explicit the value of PLK4 in surveillance and treatment of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.